Community Academic Profiles–
Profile http://med.stanford.edu/profiles/Joshua_Brody/ Email this pagePrinter friendly version
View Larger

Joshua Brody

Academic Appointments

Contact Information

  • Clinical Offices
    Oncology 875 Blake Wilbur Dr Clinic F Stanford, CA 94305-5826
    Tel Work (650) 498-6000 Fax (650) 723-7622

Professional Snapshot

Clinical Focus

  • Cancer
  • Burkitt's Lymphoma
  • Hodgkin's Disease - Medical Oncology
  • Lymphoma
  • Non-Hodgkin's Lymphoma
View all 7clinical focus of Joshua Brody

Honors and Awards

  • Program Project Grant - SUMC Blood and Marrow Transplantation, NIH (3/07-3/12)
  • Investigators Award in Clinical Translation of Gene Therapy for Cancer $1M (Co-Investigator), Alliance for Cancer Gene Therapy (12/07 - 12/11)
  • Special Fellow in Clinical Research (SFCR), The Leukemia & Lymphoma Society (deferred)
  • Clinical Investigator -- Career Development Award, Lymphoma Research Foundation (07/2007 - 06/2010)

Professional Education

BA: Harvard University, Molecular and Cellular Biology (1996)
MD: SUNY Stony Brook Medical School, Medicine (2000)
Internship: Yale - New Haven Hospital, CT (2001)
Board Certification: Internal Medicine, American Board of Internal Medicine (2003)
Residency: Yale - New Haven Hospital, CT (2003)
View All 7

Graduate & Fellowship Program Affiliations

Scientific Focus

Research Interests

Also see:

http://sarcomaca.asco.org/ASCO/Meetings/ASCO+Annual+Meeting/Past+Annual+Meetings/2008+Annual+Meeting/2008+ASCO+Daily+News/Categories/Award+Winners/Bradley+Stuart+Beller+Award+Winner+Breaks+through+Lymphoma+Vaccine+Barrier

http://www.lymphoma.org/atf/cf/%7B0363CDD6-51B5-427B-BE48-E6AF871ACEC9%7D/LYMPH_SUMMER07.PDF
for more information.

We have two ongoing clinical trials designed to use a patient's immune system to eliminate their own cancer. The first trial is currently accruing patients with low-grade B cell lymphomas and have superficially accessible disease. One such site is treated with low dose external beam radiation along with intra-tumoral injection of an immunostimulant called 'CpG'. This vaccination maneuver is intended to educate the immune system to target lymphoma cells throughout the body. We have seen extremely encouraging results and no serious side effects amongst the first groups of patients treated. These results were initially presented at ASCO 2008 and received "highest ranking abstract" for that year. We intend to treat approximately 25 more patients over then next 2 years.

Another trial will open shortly is of novel strategy called 'immunotransplant' which increases the power of cancer vaccines. This study is specifically for patients with newly diagnosed mantle cell lymphoma. We have recently published pre-clinical results of this approach in Blood,113;85-94, 2009. We hope to enroll 30 patients in this study over the next 3 years.
For more information on either of these studies, please contact our Clinical Research Coordinator at 650-725-4968.

Stanford Medicine Resources:

Footer Links: